clinical trial · NCT07933510
Changes in Symptom and Quality of Life in Patients With Uncontrolled Asthma Treated With Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI)
AsthmaUncontrolled AsthmaAsthma-COPD OverlapBudesonide/Glycopyrronium/Formoterol fumarate metered dose inhaler
brief summary
This is a single arm, prospective non-interventional study with primary data collection in patients initiated BGF MDI treatment as part of routine clinical care. In this study, 200 patients will be enrolled from approximately 20 sites mainly in general hospitals with respiratory/allergy/asthma specialists in Japan.
started
Jan 29, 2027
primary completion
Aug 31, 2027
completion
Aug 31, 2027
last updated
Nov 12, 2026
official title
BENTEN Study: Changes in Symptom and Quality of Life in Patients With Uncontrolled Asthma Treated With Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI): a Prospective, Multi-centers, Observational Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol